Zhejiang DiAn Diagnostics Co (SHE:300244) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang DiAn Diagnostics Co (300244)
Zhejiang DiAn Diagnostics Co (SHE:300244) has a market capitalization of $1.77 Billion (CN¥12.09 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #6730 globally and #1553 in its home market, demonstrating a -1.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang DiAn Diagnostics Co's stock price CN¥19.34 by its total outstanding shares 624979436 (624.98 Million). Analyse 300244 cash flow metrics to see how efficiently the company converts income to cash.
Zhejiang DiAn Diagnostics Co Market Cap History: 2015 to 2026
Zhejiang DiAn Diagnostics Co's market capitalization history from 2015 to 2026. Data shows change from $3.20 Billion to $1.77 Billion (-6.55% CAGR).
Zhejiang DiAn Diagnostics Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang DiAn Diagnostics Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Zhejiang DiAn Diagnostics Co's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.20 Billion | $1.86 Billion | $174.79 Million | 1.72x | 18.32x |
| 2016 | $2.66 Billion | $3.82 Billion | $262.76 Million | 0.69x | 10.11x |
| 2017 | $1.96 Billion | $5.00 Billion | $349.59 Million | 0.39x | 5.61x |
| 2018 | $1.26 Billion | $6.97 Billion | $388.61 Million | 0.18x | 3.25x |
| 2019 | $1.84 Billion | $8.45 Billion | $347.28 Million | 0.22x | 5.31x |
| 2020 | $2.87 Billion | $10.65 Billion | $802.93 Million | 0.27x | 3.57x |
| 2021 | $2.82 Billion | $13.08 Billion | $1.16 Billion | 0.22x | 2.42x |
| 2022 | $2.12 Billion | $20.28 Billion | $1.43 Billion | 0.10x | 1.48x |
| 2023 | $2.02 Billion | $13.41 Billion | $307.46 Million | 0.15x | 6.58x |
| 2024 | $1.04 Billion | $12.20 Billion | -$357.28 Million | 0.09x | N/A |
Competitor Companies of 300244 by Market Capitalization
Companies near Zhejiang DiAn Diagnostics Co in the global market cap rankings as of May 4, 2026.
Key companies related to Zhejiang DiAn Diagnostics Co by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Zhejiang DiAn Diagnostics Co Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang DiAn Diagnostics Co's market cap moved from $3.20 Billion to $ 1.77 Billion, with a yearly change of -6.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.77 Billion | +22.02% |
| 2025 | CN¥1.45 Billion | +39.65% |
| 2024 | CN¥1.04 Billion | -48.67% |
| 2023 | CN¥2.02 Billion | -4.54% |
| 2022 | CN¥2.12 Billion | -24.80% |
| 2021 | CN¥2.82 Billion | -1.73% |
| 2020 | CN¥2.87 Billion | +55.47% |
| 2019 | CN¥1.84 Billion | +46.09% |
| 2018 | CN¥1.26 Billion | -35.70% |
| 2017 | CN¥1.96 Billion | -26.13% |
| 2016 | CN¥2.66 Billion | -17.03% |
| 2015 | CN¥3.20 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Zhejiang DiAn Diagnostics Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.77 Billion USD |
| MoneyControl | $1.77 Billion USD |
| MarketWatch | $1.77 Billion USD |
| marketcap.company | $1.77 Billion USD |
| Reuters | $1.77 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang DiAn Diagnostics Co
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated… Read more